SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena > Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

$COCK is trending as the community rallies around its real-world asset integration through Cocky Wings LLC, a food truck business that fuels buybacks, and its partnership with $SNEK energy drinks. Community members are actively discussing locking tokens for passive income in the MemeFi arena and celebrating the growing utility within the Cardano ecosystem. The focus remains on building value and expanding the brand's reach through strategic events and partnerships.

Trump For President

Trump Crypto is trending amidst discussions about political donations and the former president's involvement in the crypto space, including scrutiny over the performance and potential scams associated with Trump-branded cryptocurrencies. The community is debating the coin's fundamentals, potential for returns, and the ethics of political figures profiting from crypto ventures. Tariff policies and their impact, particularly concerning trade with Canada, are also being discussed in relation to the coin.

Just a dead guy

The newly listed DEADGUY token is gaining attention, with the community actively sharing the contract address. The coin's branding and novelty appear to be key drivers of interest. Increased community engagement is focused on the token's potential.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound (COMP) is trending as community members debate its potential for a breakout above $40, while others express concerns about its financial sustainability and governance. Discussions also involve its position in the Real World Asset (RWA) space and comparisons to other DeFi platforms. Overall, the conversation reflects a mix of hope for future gains and skepticism regarding its current performance.

XYO is the original and one of the largest Decentralized Physical Infrastructure Networks (DePIN), boasting over 10 million nodes and consistently leading DePIN in both scale and revenue generation. Launching its Mainnet ahead of any other DePIN, XYO specializes in collecting and validating real-world data, bridging it seamlessly to Web3 and Web2 companies across AI, geolocation, and other critical data sectors. At the core of XYO are Proof of Location and Proof of Origin technologies, enabling accurate validation of real-world data for innovative use cases such as Real-World Asset (RWA) tracking, DePIN applications, real-world gaming, and treasure hunts. Recently, XYO expanded its ecosystem by launching the XYO Layer One blockchain, purpose-built to support the intensive data demands of DePIN, RWA, AI, and similar data-driven industries. XYO employs a unique dual-token model: XYO Token: An externally traded token supporting the DePIN ecosystem, rewards, staking, and governance, enhancing overall ecosystem value and scarcity.   XL1 Token: Internal to the XYO Layer One blockchain, facilitating transactions, gas fees, and other blockchain-specific use cases. The dual-token economics are strategically designed to increase scarcity and promote sustainable growth. The XYO token is available on major exchanges, including Coinbase. The XL1 token will launch publicly later in 2025. To accelerate network adoption and growth, XYO created the popular COIN app. Beyond the XYO Foundation, the team founded the U.S.-based, for-profit entity XY Labs Inc., notable as the first U.S. crypto company qualified by the SEC for a Regulation A offering, permitting share sales to both accredited and non-accredited investors. XY Labs further stands out as one of the pioneering U.S. companies to tokenize and publicly list its shares. These tokenized shares trade as $XYLB on the tZERO ATS, positioning XY Labs prominently in the growing wave of Real-World Asset (RWA) tokenization.

XYO Network

XYO Network is trending amidst discussions about its potential and frustration over price movement, with some traders pointing to pump-and-dump patterns. The community is actively discussing the upcoming Layer 1 release and potential partnerships while expressing concerns about marketing and the token's utility. Some community members express frustration with the performance and speculate about future price movements.

Clanker is an autonomous agent for deploying tokens. Currently, users may request clanker to deploy an ERC-20 token on Base by tagging it @clanker on Farcaster.

tokenbot

Tokenbot ($CLANKER) is trending due to a recent acquisition by Farcaster and reported strong revenue generation, leading to a price surge. The community is actively discussing its potential, citing its small supply and comparing its market cap to similar projects. Bullish indicators, including aggressive buybacks and high trading volume, are also fueling the conversation.

Banco de Chile SA engages in the provision of banking services. It operates through the following segments: Retail Banking, Wholesale Banking, Treasury, and Money Markets, and Subsidiaries. The Retail Banking segment consists of consumer loans, commercial loans, checking accounts, credit cards, credit lines, and mortgage loans. The Wholesale Banking segment includes corporate clients and large companies where the product offering focuses on commercial loans, checking accounts and liquidity management services, debt instruments, foreign trade, derivative contracts, and leases. The Treasury and Money Markets segment comprises securities portfolio, derivatives positions, and currency trading. The Subsidiaries segment corresponds to companies and corporations controlled by the bank. The company was founded on October 28, 1893 and is headquartered in Santiago, Chile.

Banco de Chile - ADR

Banco de Chile

Banco de Chile ($BCH) is trending as LEAPS options activity heats up, with community members discussing potential ROI on call options expiring in 2026. Some see the stock breaking out to multi-year highs, citing strong technical indicators and AI-driven buy recommendations, while others highlight recent analyst rating updates and potential risks.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin ($BNKR) is gaining attention as community members highlight its integration with the x402 protocol and AI bot for token creation, sparking excitement around its potential. Bullish sentiment is fueled by its low supply dynamics, fee-sharing model, and ties to a broader ecosystem, although some express concerns about its large total supply. The community is actively discussing its potential listing on major exchanges and its role in the Base App ecosystem.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending with community members citing bullish chart patterns like golden cross and cup and handle formations, alongside strong fundamentals. Investors are also discussing potential partnerships with tech companies, particularly around BlackBerry's QNX technology, and its growing presence in the automotive and IoT sectors. Some traders are expressing concerns about potential market manipulation.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network's token, REACT, is trending as the community focuses on its potential following the upcoming sunsetting of PRQ, which many believe has been holding it back. Community members are excited about new exchange listings and the increasing number of token holders, suggesting growing adoption and a possible price surge. Some investors speculate about REACT's potential to automate processes across different blockchains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Lyra Therapeutics, Inc. (LYRA) rose 19% on Monday after the company stated that it intends to proceed with an additional clinical trial for its lead product candidate for chronic rhinosinusitis.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/06/3161569/0/en/Lyra-Therapeutics-Announces-Clinical-Plan-for-LYR-210-and-Late-Breaking-Oral-Presentation-of-Phase-3-ENLIGHTEN-2-Study.html">stated</a> that the U.S. Food and Drug Administration confirmed at a meeting in September that an additional trial was required for the submission of a new drug application for LYR-210 in the treatment of chronic rhinosinusitis without nasal polyps. The design of the new trial will be based on the learnings from previous trials, as well as feedback from the FDA, the company said."We look forward to continuing the development of LYR-210 as a six-month treatment option for millions of patients who do not respond to standard CRS medical management,” CEO Maria Palasis said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LYRA">LYRA stock</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1364/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_06_at_2_16_16_PM_png_84207e66c2.webp" alt="LYRA's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Oct. 06, 2025 | Source: Stocktwits" width="1364" height="130"><figcaption>LYRA's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Oct. 06, 2025 | Source: Stocktwits</figcaption></figure>In June, Lyra announced positive results from a late-stage trial of LYR-210 in adult patients with CRS. It demonstrated statistically significant improvement compared to sham control in key symptoms of chronic rhinosinusitis, such as nasal obstruction, nasal discharge, and facial pain/pressure at week 24 in patients with or without nasal polyps in the trial.LYR-210 is an investigational bioabsorbable nasal implant for the treatment of chronic rhinosinusitis (CRS) in patients who have failed current therapies and require further intervention. It is designed to be inserted in a simple, in-office procedure and intended to deliver six months of continuous anti-inflammatory therapy, mometasone furoate, to the sinonasal passages for the treatment of CRS.LYRA stock is down 19% this year and approximately 25% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spruce-biosciences-stock-more-than-quadruples-after-breakthrough-therapy-designation-to-therapy-for-rare-fatal-genetic-disease/ch6R7WfR3gl">Why Did Spruce Biosciences Stock Quadruple Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Lyra Therapeutics To Conduct One More Trial For Chronic Rhinosinusitis Treatment Candidate

The company stated that the design of the new trial will be based on the learnings from the previous trials, in addition to FDA feedback.

Equity

Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates

Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of +4.84% and +26.21%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -100.00% and -1.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why

Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success

Shares of Lyra Therapeutics, Inc. (LYRA) rocketed 370% on Monday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.lyratherapeutics.com/news-releases/news-release-details/lyra-therapeutics-reports-positive-results-enlighten-2-phase-3">announced</a> positive results from its late-stage clinical trial of LYR-210 in adult patients with chronic rhinosinusitis.LYR-210 is an investigational bioabsorbable nasal implant for the treatment of chronic rhinosinusitis (CRS) in patients who have failed current therapies and require further intervention.It is designed to be inserted in a simple, in-office procedure and intended to deliver six months of continuous anti-inflammatory therapy, mometasone furoate, to the sinonasal passages to treat CRS.LYR-210 demonstrated statistically significant improvement compared to sham control in key symptoms of chronic rhinosinusitis, such as nasal obstruction, nasal discharge, and facial pain/pressure at week 24 in patients with or without nasal polyps in the trial, the company said.The trial enrolled approximately 180 CRS patients who had not had prior ethmoid sinus surgery. While some received the company’s lead product, others received a sham control.The implant was well-tolerated, and most commonly reported adverse events included epistaxis, upper respiratory tract infection, chronic sinusitis, acute sinusitis, nasopharyngitis, COVID-19, and headache, the company added.Lyra said that its therapy is expected to help the estimated four million CRS patients in the United States who fail medical management each year.Lyra CEO Maria Palasis stated that the company now plans to align with the FDA on the path forward for submitting a new drug application.The company had previously conducted a late-stage study for the implant, which did not meet its goals.On Stocktwits, retail sentiment around Lyra jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:630/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_02_at_2_05_49_PM_png_c936942df7.webp" alt="LYRA's Sentiment Meter and Message Volume as of 2:05 p.m. ET on June 2, 2025 | Source: Stocktwits" width="630" height="62"><figcaption>LYRA's Sentiment Meter and Message Volume as of 2:05 p.m. ET on June 2, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/LYRA">LYRA stock</a> is up by about 116% this year and by about 43% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/crowdstrike-and-microsoft-team-up-to-simplify-cyber-threat-intelligence/chkYeQARbH1">CrowdStrike And Microsoft Team Up To Simplify Cyber Threat Intelligence: Retail’s Buoyant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Lyra Therapeutics Stock Skyrockets On Positive Trial Data For Its Nasal Implant: Retail’s Thrilled

LYR-210 demonstrated statistically significant improvement compared to sham control in key symptoms of chronic rhinosinusitis, such as nasal obstruction, nasal discharge, and facial pain/pressure at week 24. 

Lyra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Latest Ratings for LYRA
 DateFirmActionFromTo May 2020B of A SecuritiesInitiates Coverage OnBuy May 2020JefferiesInitiates Coverage OnBuy
 View More Analyst Ratings for LYRA

 View the...

Why Lyra Therapeutics Stock Is Down 93% Today

Lyra Therapeutics shares are trading lower by 93% to $0.30 during Monday's session. The company announced the ENLIGHTEN 1 trial did not meet its primary endpoint.
read more...

The volume for Lyra Therapeutics stock increased for one day, resulting in a record-breaking daily growth of 516% of the 65-Day Volume Moving Average

LYRA's total volume now sits at 2M. The +0.16% price change was insignificant, leaving IBM's price at $6.23...

Lyra Therapeutics (LYRA, $6.13) entered Downtrend as Momentum indicator drops below 0 level on Mar 26, 2024

This indicator may be signaling that LYRA's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA.

Lyra Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

LYRA
Lyra Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LYRA News

LYRALyra Therapeutics Inc